Amgen, Inc. vs VICI Properties Inc — how do they compare? Amgen, Inc. trades at $414.88 (market cap $224.14B), while VICI Properties Inc trades at $25.97 (market cap $28.61B). The key difference: Amgen, Inc. is far larger — about 7.8× VICI Properties Inc's market cap, and VICI Properties Inc pays the higher dividend (6.93%). Which is the better fit depends on your goals.
| AMGN | VICI | |
|---|---|---|
Market Cap | $224.14B | $28.61B |
Sector | Health | Real Estate |
52-Week High | $417.20 | $33.78 |
52-Week Low | $271.18 | $25.94 |
Enterprise Value | $267.45B | $46.16B |
Dividend Yield | 2.43% | 6.93% |
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
VICI Properties trades at $25.99, down 0.33% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed Q2 2026 earnings with an EPS miss but revenue beat, while maintaining strong profitability margins near 67%. Recent news highlights a $1.75 billion notes offering and positive dividend coverage, with analysts largely bullish.
Outlook remains positive given a 6.6% dividend yield, low P/E of 10.07, and consensus price target of $29.83 implying 15% upside. Risks include earnings volatility, high leverage with $843.61M interest expense, and macroeconomic sensitivity affecting real estate valuations.
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →